Latest Breaking News On - Major adverse events - Page 2 : comparemela.com

AITRICS to Participate in HIMSS USA 2024

AITRICS to Participate in HIMSS USA 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesSoult ukpyolsiJiyoon leeManagement systems societyGlobal health conference exhibitionPredicting patientHealth conferenceHealthcare informationMajor adverse events

AITRICS to Participate in HIMSS USA 2024

- Three consecutive years of participation in HIMSS USA- Showcasing 'VitalCare' which is an AI Solution for Predicting Patient Deterioration. SEOUL, South Korea, March 12, 2024 /PRNewswire/ AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology announced on the 11th that it would participate in the 'HIMSS Global Health Conference & Exhibition' (2024.

Soult ukpyolsiSouth koreaUnited statesManagement systems societyGlobal health conference exhibitionPredicting patientHealth conferenceHealthcare informationMajor adverse events

Sequana Medical NV: Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis

Sequana Medical NV: Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesTimur reschCian crosbieStefan klotterCompany or sequanamedicalHealth solutionsDrug administrationEuronext brusselsPremarket approvalGlobal vice presidentSequana medicalChief executive officerNorth americanPivotal cohortMajor adverse eventsNorth american consortium

Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis

Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTimur reschCian crosbieHealth solutionsDrug administrationCompany or sequanamedicalSequana medicalEuronext brusselsPremarket approvalGlobal vice presidentChief executive officerNorth americanPivotal cohortMajor adverse eventsNorth american consortiumEnd stage liver

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-up .

United statesWilliam brent keelingMona ranadeJuan carlos sernaMachanahalli balakrishnaAmerican heart associationEmory university school of medicinePulmonary embolism response teamDepartment of surgeryDavid geffen school of medicineAngiodynamics incScientific affairsCompany alphavac multipurpose mechanical aspirationAcute pulmonary embolism extraction trialAlphavac systemAlphavac multipurpose mechanical aspiration